COMPANIES · AI APPLICATIONS
Isomorphic Labs
Isomorphic Labs is an Alphabet-owned AI drug-discovery company, spun out of Google DeepMind, that uses AI models descended from AlphaFold to design new medicines for pharmaceutical partners.
Isomorphic Labs is an Alphabet-owned AI drug-discovery company, spun out of Google DeepMind, that uses AI models descended from AlphaFold to design new medicines for pharmaceutical partners.
Isomorphic Labs raised $2.1 billion in May 2026, one of the largest funding rounds ever for an AI drug-discovery company, and has signed multi-billion-dollar collaboration deals with major pharmaceutical companies, showing how frontier AI research is being commercialized in medicine.
Isomorphic Labs earns upfront payments, research funding, and milestone and royalty payments from pharmaceutical partners in exchange for AI-designed drug candidates.
United Kingdom (London)
AI applications. Companies putting AI to work in real products across healthcare, finance, coding, legal, defense and more. This is where AI actually reaches everyday users and businesses.
Same-layer peers share an editorial stack classification; that alone does not establish direct competition.
Connections (3)
Every connection below is tied to a readable source, date, classification and statement of its limits. A company source establishes what that company stated; it does not necessarily provide independent confirmation.
Current relationships (3)
Source: Source undated · reviewed 2026-09-20
Evidence: Secondary reporting (unconfirmed by primary parties) · Active ownership
Limits: Confirms Isomorphic Labs' status as an Alphabet-owned subsidiary; this map represents Alphabet through its Google node, so the relationship is shown as sourced from Google rather than a separate Alphabet Inc. entity.
Isomorphic Labs ↗Source: Source undated · reviewed 2026-09-20
Evidence: Primary-source statement · Active infrastructure relationship
Limits: Confirms use of Google Cloud infrastructure as described in a Google-published case study; does not disclose contract value or whether Isomorphic Labs also uses other compute providers.
How Isomorphic Labs uses machine learning models to explore new frontiers in drug discovery ↗Source: Source undated · reviewed 2026-09-20
Evidence: Secondary reporting (unconfirmed by primary parties) · Active technology lineage
Limits: Confirms the technology lineage and spin-out relationship; does not disclose current data-sharing arrangements or IP licensing terms between the two entities.
Isomorphic Labs ↗DeepMind Spinout Isomorphic Labs Raises $2.1 Billion to Design Drugs With AI ↗
Reviewed
Inclusion in this database is not an endorsement of a company or its securities. Nothing here is a recommendation to buy or sell anything, and none of it is individualized investment advice. See the disclosures. Data: AI Map v3.22, released .